Danielle Fry Email

Chief Legal Officer & Chief Operating Officer . Ensho Therapeutics

Current Roles

Employees:
10
Revenue:
$1.6M
About
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company’s initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Ensho’s assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the company’s pipeline.
Ensho Therapeutics Address

null, null
United States
Ensho Therapeutics Email

Past Companies

Eisai USAssistant General Counsel
Eisai USSenior Counsel
Eisai USAssociate Senior Counsel